Note 11– Significant Customers

Revenue for the three months ended June 30, 2021 and 2020 was $9.1 million and $3.6 million, respectively. Two diagnostic services clients accounted for 24.9% and 16.8% of our revenue for the three months ended June 30, 2021. No contract manufacturing customer accounted for a significant portion of our revenue for the three months ended June 30, 2021. Three third-party contract manufacturing customers accounted for 58.7%, 16.6% and 12.2%, respectively, of our revenue from continuing operations for the three months ended June 30, 2020. The loss of sales to any of these large customers could have a material adverse effect on our business operations and financial condition.

Revenue for the six months ended June 30, 2021 and 2020 was $24.4 million and $5.5 million, respectively. Two diagnostic services clients accounted for 38.5% and 24.0%, respectively, of our revenue for the six months ended June 30, 2021. Two third-party contract manufacturing customers accounted for 55.2% and 17.1%, respectively, of our revenue for the six months ended June 30, 2020. The loss of sales to any of these large customers could have a material adverse effect on our business operations and financial condition.

Three diagnostic services clients generated 38.9%, 21.0% and 10.2% of our total reimbursement receivable balances from government agencies and healthcare issuers at June 30, 2021. Two consumer product customers represented 72.4%, and 12.8% of our total trade receivable balances at June 30, 2020.